HPS Pharmacies wish to advise that Janssen-Cilag Pty Ltd, in consultation with the Therapeutic Goods Administration, have given notice of an urgent drug recall of:
Jurnista® 16mg Prolonged Release Tablets x 14
Aust R: 141533
Batch number: ECLS200
Expiry Date: 29 February 2016
This batch of Jurnista® (hydromorphone hydrochloride) 16mg prolonged release tablets has been recalled due to being released without the tamper evident seals applied, however, a statement on the box indicates that the seals should be intact.
There is not expected to be any interruption to the continuity of supply of Jurnista® 16mg prolonged release tablets as alternative batches are currently in circulation.
No adverse events associated with this batch have been reported and no other batches or presentations of Jurnista® tablets are affected by this notice.
Those facilities who choose to remove tablet blister strips from the outer box may continue to use the enclosed tablets. Those facilities that store controlled substances within the supplied tamper evident boxes should inspect stocks and quarantine all units that are in original condition for return to your supplier. Any items supplied by HPS Pharmacies should be returned to the pharmacy for processing.
Retain this notice in a prominent position, including in other related business units until normal supply resumes. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Janssen Customer Service on 1800 226 334.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.